The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass

The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01619436

Enrollment

Registered

2012-06-14

Start date

2011-01-31

Completion date

2012-05-31

Last updated

2012-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glycemia During Coronary Artery Bypass Graft, Sedation During Pre-anesthetic Medication

Brief summary

The purpose of this study is the randomized blind research of the assessment of the different levels of glycemia during Coronary Artery Bypass Graft (CABG) with cardiopulmonary by-pass (CPB) between clonidine and placebo. As clonidine decrease the inflammatory response during cardiac surgery, the investigators would like to know if the glycemia levels in clondine group will be lower than placebo group.

Interventions

DRUGClonidine

bolus, clonidine 2 mg/kg IV

DRUGRinger lactato

1 ML ringer lactato IV, as placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

45 Years to 80 Years

Healthy volunteers

Inclusion criteria

* elective CABG EF \> 40% Sinus ritmy

Exclusion criteria

* precordialgia emergency surgery combinated surgery not agreement

Design outcomes

Primary

Measure	Time frame	Description
sedation	2 years	Clonidine 2 mg/kg IV. assessment sedation with Ransay scale

Secondary

Measure	Time frame	Description
Glycemia	2 years	clonide 2 mg/kg. assessment the glycemia during CPB.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026